 SAN DIEGO, June 24, 2021 PRNewswire -- Viking Therapeutics, Inc. Viking NASDAQ: VKTX, a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of a Phase 1b clinical trial of VK0214, a novel small molecule agonist of the thyroid hormone receptor beta TRβ, in patients with X-linked adrenoleukodystrophy X-ALD. The study is open to enrollment at clinical sites within the United States. 